Search clinical trials for: Letrozole

Total 667 results

BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Hormone Receptor Positive Malignant Neoplasm of Breast | HER2-negative Breast Cancer | Hormone-receptor-positive Breast Cancer

China
Northwestern University
National Cancer Institute (NCI)

Recruiting

Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast Cancer

Israel
Centro Nacional de Investigaciones Oncologicas...
Dr. Miguel Angel Quintela Fandiño (CNIO); Dr, Ramón Colomer i Bosch; FUNDACIÓN...

Completed

Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics

Breast Cancer

Spain
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer (FEMZONE)

Breast Neoplasms

Germany
Cairo University

Completed

Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome. (FSH)

Infertility

Egypt
Memorial Sloan Kettering Cancer Center
Verastem, Inc.

Recruiting

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer (CHAMELEON)

Low-Grade Serous Ovarian Cancer

United States
Novartis Pharmaceuticals

Active, not recruiting

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (AMALEE)

Breast Cancer

United States, South Africa, Austria, Hungary, Germany, Czechia, France, Russian Federation, Thailand, Belgium, Bulgaria, Lithuania, Jordan, Sweden, Finland, Peru, Colombia, Portugal, Canada, Brazil, India, Argentina, Costa Rica
Eli Lilly and Company

Active, not recruiting

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3)

Breast Cancer

Canada, Germany, Australia, Japan, United States, Taiwan, Belgium, New Zealand, Italy, Israel, Spain, France, Netherlands, Mexico, Turkey, United Kingdom, Korea, Republic of, Austria, Puerto Rico, Sweden, Russian Federation, Greece, Slovaki...
MedSIR
Cellestia Biotech AG

Terminated

CB-103 Plus NSAI In Luminal Advanced Breast Cancer (CAILA)

Advanced Breast Cancer

Spain
Stanford University

Completed

Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole

Short Stature

United States
NYU Langone Health

Completed

Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors

Brain and Central Nervous System Tumors

United States
National Cancer Centre, Singapore

Unknown

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Breast Cancer

Singapore
Mridula George, MD

Recruiting

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Breast Cancer

United States
National Taiwan University Hospital

Recruiting

A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC (ORACLE-RIPA)

Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Therapy

Taiwan
Jules Bordet Institute
Hoffmann-La Roche

Recruiting

Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) (ROSALINE)

HER2-negative Breast Cancer | ER+ Breast Cancer | Invasive Lobular Breast Carcinoma

Belgium, France
Pfizer

Completed

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

Breast Neoplasms

United States, Canada, Spain, United Kingdom, Australia, Belgium, Korea, Republic of, Japan, Czechia, France, Germany, Hungary, Ireland, Italy, Poland, Russian Federation, Taiwan, Ukraine
NYU Langone Health
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer

Brain and Central Nervous System Tumors

United States, Australia
International Peace Maternity and Child Health...

Recruiting

The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)

Infertility, Female | Letrozole

China
Erasme University Hospital
University Hospital, Lille

Recruiting

Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE) (fAMHOPE)

Breast Neoplasm Malignant Female

France, Italy, Belgium
Baylor Breast Care Center
GlaxoSmithKline; Translational Breast Cancer Research Consortium

Active, not recruiting

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy (HELEX)

Breast Cancer

United States
University Medical Center Groningen

Completed

Palbociclib and FES PET

Breast Cancer

Netherlands
NHS Tayside

Completed

Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers (BARONET)

Breast Cancer

United Kingdom
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

Breast Cancer

United States, Puerto Rico
Assiut University

Not yet recruiting

Cost Effectiveness Analysis for Induction of Ovulation in the Polycystic Ovary Syndrome by Letrozole Versus Clomiphene Citrate

Infertility
Beta Pharma (Suzhou) Co., Ltd.

Recruiting

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Advanced Solid Tumor | HR+/HER2- Breast Cancer

China
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Estrogen Receptor Positive | Postmenopausal

United States
Vanderbilt-Ingram Cancer Center

Completed

PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Bristol-Myers Squibb
US Oncology Research

Completed

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Metastatic Breast Cancer

United States
Dr. Reddy's Laboratories Limited

Completed

Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions

Healthy
Mansoura University

Completed

Letrozole or Laparoscopic Ovarian Diathermy for Women With CC Resistant Polycystic Ovary Syndrome.

Polycystic Ovary Syndrome

Egypt
Novartis Pharmaceuticals

Completed

Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight)

HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer

Canada
Fudan University

Completed

Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

Breast Cancer Female

China
Novartis Pharmaceuticals

Completed

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

Breast Neoplasms | Osteoporosis

United States, Puerto Rico
Novartis

Completed

Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

Osteoporosis | Postmenopausal

Germany
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Advanced Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive...

Australia, United States
University of Washington
National Cancer Institute (NCI)

Recruiting

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Breast Adenocarcinoma | Invasive Breast Carcinoma of No Special Type

United States
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (PLEASURABLE)

Breast Cancer

China
Gary Schwartz

Withdrawn

Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

Breast Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

Lymphoma

United States
University of California, Davis

Completed

Letrozole as a Treatment of Endometrial Cancer

Endometrial Carcinoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Mayo Clinic

Recruiting

Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

Invasive Breast Carcinoma | Breast Adenocarcinoma | Resectable Breast Carcinoma

United States
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (MONARCH plus)

Breast Cancer

China, India, South Africa, Brazil
Novartis Pharmaceuticals

Completed

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (BioItaLEE)

Breast Cancer

Italy
SOLTI Breast Cancer Research Group
Pfizer

Completed

Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy (PROMETEO II)

Breast Cancer

Spain
Nishtar Medical University

Completed

Efficacy of Letrozole Versus Clomiphene Citrate on Ovulation Induction in Patients With Polycystic Ovarian Syndrome

Polycystic Ovary Syndrome

Pakistan
NYU Langone Health
Children's Hospitals and Clinics of Minnesota; Schneider Children's Hospital

Completed

Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

Brain Tumors

United States, Canada
Shanghai Jiao Tong University School of Medicine

Completed

Traditional Chinese Medicine as Preventive Method for Osteoporosis Induced by Adjuvant Endocrine Therapy (COAT)

Breast Cancer | Osteoporosis

China
Center for Human Reproduction

Withdrawn

Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles? (Cost-Less)

Infertility

United States

Search clinical trials for: Letrozole

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations